French contract manufacturer Novacep today reported full-year earnings for 2013 that improved with an 8% jump in revenues to €316 million ($435 million). The Pompey-based drug company said that new contracts in highly potent ingredients helped offset the loss of other contracts in its synthesis business, which saw revenues grow 5.2% to €155.1 million. Its biopharma segment grew 14% to €52.5 million. The company, which has been expanding in the last couple of years, said a new management team was in place. Release | More